Tekla Capital Management LLC Ultragenyx Pharmaceutical Inc. Transaction History

Tekla Capital Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 01, 2022	BUY	$39.96 - $66.14 $907,092 - $1.5 Million	22,700 Added 51.17%	67,065 $2.78 Million
Q2 2022 Jul 29, 2022	SELL	$45.8 - $85.4 $4.41 Million - $8.23 Million	-96,361 Reduced 68.47%	44,365 $2.65 Million
Q3 2021 Nov 12, 2021	BUY	$77.92 - $102.4 $478,117 - $628,326	6,136 Added 4.56%	140,726 $12.7 Million
Q2 2021 Aug 13, 2021	BUY	$92.19 - $115.71 $3.42 Million - $4.29 Million	37,110 Added 38.07%	134,590 $12.8 Million
Q3 2019 Nov 13, 2019	BUY	$42.5 - $63.11 $2.51 Million - $3.72 Million	59,000 Added 153.33%	97,480 $4.17 Million
Q2 2019 Aug 14, 2019	SELL	$54.93 - $74.36 $2.11 Million - $2.86 Million	-38,478 Reduced 50.0%	38,480 $2.44 Million
Q2 2018 Aug 13, 2018	SELL	$48.54 - $85.31 $3.48 Million - $6.11 Million	-71,600 Reduced 48.2%	76,958 $5.92 Million
Q3 2017 Nov 13, 2017	BUY	$49.79 - $66.32 $1.06 Million - $1.41 Million	21,250 Added 16.69%	148,558 $7.91 Million
Q2 2017 Aug 14, 2017	BUY	N/A	127,308	127,308 $7.91 Million

325

85.7M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.13B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.